Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines - Wikidata - awgldk - TriplyDB

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

http://www.wikidata.org/entity/Q27013679

about

Advances in Immunotherapy for Glioblastoma Multiforme.Novel immunotherapies for the treatment of melanoma.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.The Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

P2860

Q37680966-F06918CA-5569-4A1F-8945-D83EAF79EADE Q38824190-DC5BC04A-271B-4954-93F9-F5DE6CC1A443 Q39210287-89397B5B-F6E4-458E-BE10-26CA64C8E6AE Q39372488-CE6C02A5-6065-430F-BF7E-7BF7B68C1037 Q40187007-36BE357D-D19D-4FEF-974C-172F6A8A9243 Q40348395-BB894935-FFF3-40DC-BE86-728CA54C5836 Q47121798-81B43F8C-631F-437B-90EA-F7A0804B8403 Q58750585-70A22790-EB8B-447D-8F76-F2CBC9791571

P2860

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

http://www.wikidata.org/entity/Q27013679

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@ast

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@en

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@nl

type

label

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@ast

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@en

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@nl

prefLabel

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@ast

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@en

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@nl

P1433

Q27013679-E7563FED-58DD-4C53-8FF6-F084E2657910

P1476

Q27013679-FD902E0F-C78E-40B0-B765-3380B1786DB2

P2093

Q27013679-71756014-CDB7-4D3C-B520-7AA7BA13DAB1

Q27013679-E848780E-0438-46AF-97FA-74328271E9D9

P275

Q27013679-144624A0-BEF6-47F3-AFC3-0AF67FA376C7

P2860

Q27013679-003A7424-4DDD-405E-B8D7-AF4495AA458F

Q27013679-006215F3-98B5-45C9-BF40-E4502AD90FFF

Q27013679-0113219F-7EE7-46FD-AA18-3C3C9B41BA55

Q27013679-0242927F-8E0A-4CD6-861B-2C2F34A98562

Q27013679-0460D6B5-813A-4FB8-B3F5-558A0C4A1A50

Q27013679-057EDD65-10F0-491F-9C44-907AB73B371B

Q27013679-07314D2A-EBD4-4723-9E72-968811A273AB

Q27013679-07F4EFC5-24F6-40BB-B9F7-D3CD29FF6FA9

Q27013679-0F6A5430-5969-433E-B295-721AA52CDC73

Q27013679-0FD727AB-BD2F-49C0-AEC1-33EC17CA5654

P304

Q27013679-DBF921E4-A326-44FC-B569-9A039549B9E1

P31

Q27013679-39E4229E-2D0B-4C55-BCE4-5170B2A3A176

Q27013679-F162774C-C5C3-4A95-A02B-D087DB70D8EC

P356

Q27013679-EF5D538D-F8D4-450A-926F-E1CF5E9C99F6

P407

Q27013679-799B747D-A05B-4ADA-BA7E-4B9B61FC07A9

P478

Q27013679-8DC145D8-7656-4A6B-80CA-001D5AC6F524

P50

Q27013679-2D36989B-7E5F-4A54-8129-6AD337A82933

Q27013679-5A9D6DE5-87F7-4C64-AE74-DC7C00C1D744

P577

Q27013679-E46599D0-701D-4B60-85CE-5DF4DCF97711

Q27013679-F7EBAFC1-7B32-45E8-B125-15D2FFD02333

P5875

Q27013679-6B73DBF7-4B82-417C-8DDB-82F79636FDD9

P698

Q27013679-48CCB926-6D67-4574-A97F-5B7894AEC790

P921

Q27013679-A10C9D6D-8751-4120-86C0-90C41B19414A

Q27013679-D016AFA8-80F8-490B-935C-17DB532A5985

P932

Q27013679-02B267E3-603B-4534-A8FD-5E29F6175D16

P356

P1433

Journal of Immunology Research

P1476

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

@en

P2093

Cleo Goyvaerts

http://www.w3.org/2001/XMLSchema#string

Karine Breckpot

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

Tumor-infiltrating dendritic cells in cancer pathogenesis

Naturally occurring antibodies devoid of light chains

Nanobodies: natural single-domain antibodies

Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice

Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein

Visualization of DC-SIGN-mediated entry pathway of engineered lentiviral vectors in target cells

Differential antigen processing by dendritic cell subsets in vivo

The nature of the principal type 1 interferon-producing cells in human blood

P304

785634

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2015/785634

http://www.w3.org/2001/XMLSchema#string

P407

P478

2015

http://www.w3.org/2001/XMLSchema#string

P50

Karine Breckpot

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283966061

http://www.w3.org/2001/XMLSchema#string

P698

26583156

http://www.w3.org/2001/XMLSchema#string

P921

hemic and immune systems

P932

4637118

http://www.w3.org/2001/XMLSchema#string